Grifols's Subsidiary Biotest Forecasts Approximately $1B In Revenue From Sales In The U.S. Of Its Intravenous Immunoglobulin Yimmugo During The Next Seven Years, Following Recent FDA Approval To Treat Primary Immunodeficiencies

Benzinga · 07/01 10:09
  • Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025
  • Yimmugo will be distributed by Kedrion in the U.S. as part of a broader Group channel strategy, with Grifols focusing on continued growth of its current portfolio for this market
  • It adds to Grifols' strong franchise of intravenous and subcutaneous immunoglobulins to meet growing patient demand for these therapeutics
  • Yimmugo will be followed by other proteins in the pipeline, including fibrinogen and trimodulin, both in late-stage development